Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe Systemic Lupus Erythematosus With Lupus Nephritis (RECLAIM-LN)

NCT07570862 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT07570862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07570862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe Systemic Lupus Erythematosus With Lupus Nephritis (RECLAIM-LN)
Lead sponsor
Fate Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
July 27, 2026
Completion date
January 31, 2030
Enrollment
53 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis, lupus nephritis - who class iii, lupus nephritis - who class iv, sle - systemic lupus erythematosus, systemic lupus erythematosus